FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912846872> ?p ?o ?g. }

• W2912846872 endingPage "683" @default.
• W2912846872 startingPage "670" @default.
• W2912846872 abstract "This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in five European countries. This is a combined analysis of two observational, non-interventional prospective cohort studies, one of which was conducted in Germany and France, the other in Bulgaria, Czech Republic, and Hungary. The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy. The planned duration of observation was 12 months from the first dose of panitumumab. A total of 332 patients treated with panitumumab + FOLFOX in the first line and 94 patients treated with panitumumab + FOLFIRI in the second line were analyzed. The median number of panitumumab infusions was 10.0 in first-line FOLFOX patients and 11.5 in second-line FOLFIRI patients; the median duration of panitumumab exposure was 5.7 and 6.9 months, respectively. The unadjusted overall response rate (complete or partial response) in patients with available post-baseline response assessment (n = 290) was 51.7% in first-line FOLFOX and 44.9% in second-line FOLFIRI patients. In the first-line setting, resectability was achieved in 9.3%. Reported hospitalizations were mostly cancer-related visits such as scheduled anticancer treatment administrations, tumor assessment visits, or interventions. The majority of adverse drug reactions were skin disorders, with 75.3% in first-line FOLFOX patients and 72.3% in second-line FOLFIRI patients. Overall, the study results show that treatment patterns, clinical efficacy, and the safety profile of panitumumab in routine clinical practice were comparable to those in randomized controlled trials. The relatively low skin toxicity rate could be attributed to increasing experience in managing panitumumab-associated rash and some degree of underreporting. Amgen." @default.
• W2912846872 created "2019-02-21" @default.
• W2912846872 creator A5001388674 @default.
• W2912846872 creator A5025634287 @default.
• W2912846872 creator A5028464891 @default.
• W2912846872 creator A5036539666 @default.
• W2912846872 creator A5043348604 @default.
• W2912846872 creator A5048939350 @default.
• W2912846872 creator A5068491805 @default.
• W2912846872 creator A5070534659 @default.
• W2912846872 creator A5074765601 @default.
• W2912846872 creator A5086971449 @default.
• W2912846872 date "2019-01-28" @default.
• W2912846872 modified "2023-10-18" @default.
• W2912846872 title "Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC" @default.
• W2912846872 cites W1965195516 @default.
• W2912846872 cites W1988962161 @default.
• W2912846872 cites W2012006000 @default.
• W2912846872 cites W2016366283 @default.
• W2912846872 cites W2017005150 @default.
• W2912846872 cites W2036008965 @default.
• W2912846872 cites W2085633477 @default.
• W2912846872 cites W2098354753 @default.
• W2912846872 cites W2104580737 @default.
• W2912846872 cites W2106789440 @default.
• W2912846872 cites W2108235590 @default.
• W2912846872 cites W2118571739 @default.
• W2912846872 cites W2132754339 @default.
• W2912846872 cites W2133045939 @default.
• W2912846872 cites W2151074151 @default.
• W2912846872 cites W2159179344 @default.
• W2912846872 cites W2179455134 @default.
• W2912846872 cites W2470575266 @default.
• W2912846872 cites W2518762681 @default.
• W2912846872 cites W2531319683 @default.
• W2912846872 cites W2606920054 @default.
• W2912846872 cites W2760429531 @default.
• W2912846872 doi "https://doi.org/10.1007/s12325-019-0874-6" @default.
• W2912846872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6824336" @default.
• W2912846872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30689133" @default.
• W2912846872 hasPublicationYear "2019" @default.
• W2912846872 type Work @default.
• W2912846872 sameAs 2912846872 @default.
• W2912846872 citedByCount "3" @default.
• W2912846872 countsByYear W29128468722020 @default.
• W2912846872 countsByYear W29128468722021 @default.
• W2912846872 countsByYear W29128468722022 @default.
• W2912846872 crossrefType "journal-article" @default.
• W2912846872 hasAuthorship W2912846872A5001388674 @default.
• W2912846872 hasAuthorship W2912846872A5025634287 @default.
• W2912846872 hasAuthorship W2912846872A5028464891 @default.
• W2912846872 hasAuthorship W2912846872A5036539666 @default.
• W2912846872 hasAuthorship W2912846872A5043348604 @default.
• W2912846872 hasAuthorship W2912846872A5048939350 @default.
• W2912846872 hasAuthorship W2912846872A5068491805 @default.
• W2912846872 hasAuthorship W2912846872A5070534659 @default.
• W2912846872 hasAuthorship W2912846872A5074765601 @default.
• W2912846872 hasAuthorship W2912846872A5086971449 @default.
• W2912846872 hasBestOaLocation W29128468721 @default.
• W2912846872 hasConcept C121608353 @default.
• W2912846872 hasConcept C126322002 @default.
• W2912846872 hasConcept C143998085 @default.
• W2912846872 hasConcept C2776705615 @default.
• W2912846872 hasConcept C2778260052 @default.
• W2912846872 hasConcept C2778332735 @default.
• W2912846872 hasConcept C2780259306 @default.
• W2912846872 hasConcept C2780962732 @default.
• W2912846872 hasConcept C2781187634 @default.
• W2912846872 hasConcept C526805850 @default.
• W2912846872 hasConcept C71924100 @default.
• W2912846872 hasConceptScore W2912846872C121608353 @default.
• W2912846872 hasConceptScore W2912846872C126322002 @default.
• W2912846872 hasConceptScore W2912846872C143998085 @default.
• W2912846872 hasConceptScore W2912846872C2776705615 @default.
• W2912846872 hasConceptScore W2912846872C2778260052 @default.
• W2912846872 hasConceptScore W2912846872C2778332735 @default.
• W2912846872 hasConceptScore W2912846872C2780259306 @default.
• W2912846872 hasConceptScore W2912846872C2780962732 @default.
• W2912846872 hasConceptScore W2912846872C2781187634 @default.
• W2912846872 hasConceptScore W2912846872C526805850 @default.
• W2912846872 hasConceptScore W2912846872C71924100 @default.
• W2912846872 hasFunder F4320307105 @default.
• W2912846872 hasIssue "3" @default.
• W2912846872 hasLocation W29128468721 @default.
• W2912846872 hasLocation W29128468722 @default.
• W2912846872 hasLocation W29128468723 @default.
• W2912846872 hasLocation W29128468724 @default.
• W2912846872 hasOpenAccess W2912846872 @default.
• W2912846872 hasPrimaryLocation W29128468721 @default.
• W2912846872 hasRelatedWork W1999876805 @default.
• W2912846872 hasRelatedWork W2071471252 @default.
• W2912846872 hasRelatedWork W2095257613 @default.
• W2912846872 hasRelatedWork W2168642582 @default.
• W2912846872 hasRelatedWork W2405565070 @default.
• W2912846872 hasRelatedWork W2617055067 @default.
• W2912846872 hasRelatedWork W2636687439 @default.
• W2912846872 hasRelatedWork W2999500669 @default.
• W2912846872 hasRelatedWork W4220811422 @default.

• next